Heterocyclic aspartyl protease inhibitors
View Patent ↗Disclosed are compounds of the formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein W, X, U, R 1 , R 2 , R 3 , and R 4 , are as defined herein, and pharmaceutical compositions comprising the compounds of formula I. Also disclosed is the method of inhibiting aspartyl protease, and in particular, the methods of treating cardiovascular diseases, cognitive and neurodegenerative diseases, and the methods of inhibiting of Human Immunodeficiency Virus, plasmepins, cathepsin D and protozoal enzymes. Also disclosed are methods of treating cognitive or neurodegenerative diseases using the compounds of formula I in combination with a cholinesterase inhibitor or a muscarinic antagonist.
1. A compound having the structural formula
or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein
U is a bond;
R 1 is H, alkyl, R 21 -alkyl, arylalkyl, R 21 -arylalkyl, cycloalkylalkyl, R 21 -cycloalkylalkyl, heterocycloalkyalkyl or R 21 -heterocycloalkylalkyl,
R 2 is H;
R 3 is alkyl, cycloalkylalkyl, cycloalkyl, aryl, arylalkyl, R 21 -alkyl, R 21 -cycloalkylalkyl, R 21 -cycloalkyl, R 21 -aryl or R 21 -arylalkyl;
R 4 is alkyl, cycloalkylalkyl, cycloalkyl, aryl, arylalkyl, R 21 -alkyl, R 21 -cycloalkylalkyl, R 21 -cycloalkyl, R 21 -aryl or R 21 -arylalkyl;
R 5 is H, alkyl, R 21 -alkyl, arylalkyl, R 21 -arylalkyl, cycloalkylalkyl, R 21 -cycloalkylalkyl, heterocycloalkyalkyl or R 21 -heterocycloalkylalkyl;
R 15 , R 16 and R 17 are each independently H, R 18 -alkyl, or alkyl;
each R 21 is independently alkyl, aryl, halo, —OR 15 , —NO 2 , —C(O)R 15 , —CH 2 —N(R 15 )C(O)N(R 16 )(R 17 ) or —CH(R 15 )(R 16 );
R 18 is —OR 20 ; and
R 20 is aryl.
2. A compound of claim 1 wherein
R 3 , R 4 , R 6 and R 7 are
and
R 1 and R 5 is H, CH 3 ,
3. A compound having the structural formula
or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein
U is a bond;
R 1 is H, alkyl, R 21 -alkyl, arylalkyl, R 21 -arylalkyl, cycloalkylalkyl, R 21 -cycloalkylalkyl, heterocycloalkyalkyl or R 21 -heterocycloalkylalkyl,
R 2 is H;
R 3 is alkyl, cycloalkylalkyl, cycloalkyl, aryl, arylalkyl, R 21 -alkyl, R 21 -cycloalkylalkyl, R 21 -cycloalkyl, R 21 -aryl, R 21 -arylalkyl, heteroarylalkyl, heteroaryl, heterocycloalkyl, heterocycloalkylalkyl, R 21 -heteroarylalkyl, R 21 -heteroaryl, R 21 -heterocycloalkyl or R 21 -heterocycloalkylalkyl;
R 4 is alkyl, cycloalkylalkyl, cycloalkyl, aryl, arylalkyl, R 21 -alkyl, R 21 -cycloalkylalkyl, R 21 -cycloalkyl, R 21 -aryl, R 21 -arylalkyl, heteroarylalkyl, heteroaryl, heterocycloalkyl, heterocycloalkylalkyl, R 21 -heteroarylalkyl, R 21 -heteroaryl, R 21 -heterocycloalkyl or R 21 -heterocycloalkylalkyl;
R 5 is H, alkyl, R 21 -alkyl, arylalkyl, R 21 -arylalkyl, cycloalkylalkyl, R 21 -cycloalkylalkyl, heterocycloalkyalkyl or R 21 -heterocycloalkylalkyl;
R 15 , R 16 and R 17 is are each independently H, cycloalkyl, cycloalkylalkyl, R 18 -alkyl, alkyl, aryl, R 18 -aryl, R 18 -arylalkyl, or arylalkyl
R 18 is —OR 20 or halo;
R 20 is aryl or halo substituted aryl;
each R 21 is independently alkyl, aryl, heteroaryl, R 22 -alkyl, R 22 -aryl, R 22 -heteroaryl, halo, heterocycloalkyl, —N(R 15 )(R 16 ), —OR 15 , —NO 2 , —C(O) R 15 ,—N(R 15 )C(O)R 16 , —N(R 15 )S(O) 2 R 16 , —CH 2 —N(R 15 )C(O)N(R 16 )(R 17 ), —N(R 15 )C(O)N(R 16 )(R 17 ) or —CH(R 15 )(R 16 ); and
R 22 is —OR 15 or halo.
4. A pharmaceutical composition comprising an effective amount of at least one compound of any one of claims 1 , 2 , or 3 , or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, and a pharmaceutically effective carrier.